Physician profile
Maria Mascolo
NPI 1194793042
$358,043.59
in general payments reported to CMS, 2019-2025
48 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,377 · 2020: $1,668 · 2021: $9,624 · 2022: $29K · 2023: $103K · 2024: $91K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $248K · Travel and Lodging: $35K · Consulting Fee: $16K · Food and Beverage: $16K · Education: $48.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $248,175.00 |
| Travel and Lodging | $35,169.92 |
| Consulting Fee | $16,277.00 |
| Food and Beverage | $15,672.68 |
| Education | $48.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $311,279.30 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Amgen INC. | $18,824.59 | 2022-2025 | Tezspire |
| Genzyme Corporation | $13,293.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,499.93 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,621.37 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,292.59 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Grifols USA, LLC | $1,031.91 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $916.88 | 2019-2025 | Arikayce |
| Electromed, INC. | $754.34 | 2019-2025 | Smartvest |
| Mylan Specialty L.P. | $725.13 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $685.77 | 2019-2025 | Opsumit, Opsynvi, Uptravi |
| Harmony Biosciences LLC | $563.85 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $530.08 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $516.35 | 2020-2023 | Acthar |
| United Therapeutics Corporation | $498.46 | 2019-2025 | Tyvaso, Tyvaso |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $463.56 | 2019-2025 | Winrevair, Belsomra, Keytruda |
| Axsome Therapeutics, INC. | $421.81 | 2022-2025 | Sunosi |
| Philips North America LLC | $262.25 | 2019-2024 | (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $251.85 | 2020-2025 | Glassia |
| Verona Pharma, INC. | $223.95 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $162.35 | 2021-2023 | Airduo Digihaler |
| Ani Pharmaceuticals, INC. | $150.44 | 2024-2025 | Purified Cortrophin Gel |
| Eisai INC. | $117.18 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $109.34 | 2019 | |
| Baxter Healthcare | $98.76 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Enterprises LLC | $82.93 | 2019 | |
| Circassia INC. | $74.43 | 2019 | |
| Genentech USA, INC. | $73.63 | 2019-2020 | |
| Inspire Medical Systems, INC. | $68.28 | 2023-2025 | Inspire |
| Shire North American Group INC | $64.29 | 2019 | |
| Allergan, INC. | $60.71 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $59.60 | 2024-2025 | Lumryz |
| Pfizer INC. | $53.71 | 2019-2025 | |
| Fisher & Paykel Healthcare INC | $44.70 | 2019-2021 | |
| Advanced Respiratory, INC | $43.70 | 2020-2021 | |
| Inogen, INC. | $32.24 | 2023 | Inogen |
| Idorsia Pharmaceuticals US INC | $29.81 | 2023-2025 | Quviviq, Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $24.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.07 | 2023 | |
| Lilly USA, LLC | $13.60 | 2025 | Mounjaro |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Mascolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.